Cargando…

Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses

BACKGROUND: Preclinical data suggest cell cycle checkpoint blockade may induce an immunostimulatory tumor microenvironment. However, it remains elusive whether immunomodulation occurs in the clinical setting. To test this, we used blood and fresh tissue samples collected at baseline and post therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lampert, Erika J, Cimino-Mathews, Ashley, Lee, Joo Sang, Nair, Jayakumar, Lee, Min-Jung, Yuno, Akira, An, Daniel, Trepel, Jane B, Ruppin, Eytan, Lee, Jung-Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380948/ https://www.ncbi.nlm.nih.gov/pubmed/32709712 http://dx.doi.org/10.1136/jitc-2019-000516

Ejemplares similares

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer
por: Nair, Jayakumar, et al.
Publicado: (2020)

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer
por: Brill, Ethan, et al.
Publicado: (2017)

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2 study
por: Lee, Jung-Min, et al.
Publicado: (2018)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
por: Dai, Jie, et al.
Publicado: (2023)

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2023)

Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma
por: Woeste, Matthew R, et al.
Publicado: (2023)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort
por: Bai, Xue, et al.
Publicado: (2021)

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
por: Yoshikawa, Akie Kimura, et al.
Publicado: (2022)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials
por: Silbert, Sara K., et al.
Publicado: (2023)

Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study
por: Bae, Seongman, et al.
Publicado: (2021)

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
por: Park, Junsik, et al.
Publicado: (2023)

Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer
por: Ardizzoni, Andrea, et al.
Publicado: (2021)

High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer
por: Park, Hyung Soon, et al.
Publicado: (2021)

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
por: Wu, Si-Yu, et al.
Publicado: (2021)

Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2021)

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
por: Elkrief, Arielle, et al.
Publicado: (2023)

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
por: Jeong, Seongju, et al.
Publicado: (2021)

EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer
por: Lee, Kevin J., et al.
Publicado: (2020)

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2022)

High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer
por: Bareche, Yacine, et al.
Publicado: (2021)

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib
por: Blosser, Wayne D., et al.
Publicado: (2020)

Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity
por: Hong, Tae Hee, et al.
Publicado: (2020)

Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
por: Pyo, Kyoung-Ho, et al.
Publicado: (2020)

Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

Automated synthesis of prexasertib and derivatives enabled by continuous-flow solid-phase synthesis
por: Liu, Chenguang, et al.
Publicado: (2021)

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
por: Jung, Hyun Ae, et al.
Publicado: (2022)

Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy
por: Lee, Jii Bum, et al.
Publicado: (2022)

Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation
por: Chong, Gun Oh, et al.
Publicado: (2020)

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
por: Starzer, Angelika M, et al.
Publicado: (2021)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
por: Cristescu, Razvan, et al.
Publicado: (2022)

Siglec-9(+) tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer
por: Wang, Yiying, et al.
Publicado: (2023)

IMMU-17. CAR T CELLS TARGETING THE INTEGRIN ALPHA(V)BETA(3) EXHIBIT ROBUST ANTI-TUMOR RESPONSES AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND GLIOBLASTOMA (GBM)
por: Cobb, Dustin, et al.
Publicado: (2020)

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
por: Kwon, Minsuk, et al.
Publicado: (2022)

CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer
por: Yang, Moran, et al.
Publicado: (2021)

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Novel cytokine–antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma
por: Chu, Yaya, et al.
Publicado: (2020)

DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy
por: Ged, Yasser, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gjj3ohebsk2ku5masa2ct9oqgi